EP3429590A4 - Methods and compositions for treating a neurodegenerative disorder in a sphingotyped subject - Google Patents

Methods and compositions for treating a neurodegenerative disorder in a sphingotyped subject Download PDF

Info

Publication number
EP3429590A4
EP3429590A4 EP17767536.0A EP17767536A EP3429590A4 EP 3429590 A4 EP3429590 A4 EP 3429590A4 EP 17767536 A EP17767536 A EP 17767536A EP 3429590 A4 EP3429590 A4 EP 3429590A4
Authority
EP
European Patent Office
Prior art keywords
sphingotyped
compositions
treating
subject
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP17767536.0A
Other languages
German (de)
French (fr)
Other versions
EP3429590A1 (en
Inventor
Peter T. Lansbury
Craig Justman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lysosomal Therapeutics Inc
Original Assignee
Lysosomal Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lysosomal Therapeutics Inc filed Critical Lysosomal Therapeutics Inc
Publication of EP3429590A1 publication Critical patent/EP3429590A1/en
Publication of EP3429590A4 publication Critical patent/EP3429590A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
EP17767536.0A 2016-03-16 2017-03-16 Methods and compositions for treating a neurodegenerative disorder in a sphingotyped subject Withdrawn EP3429590A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662309231P 2016-03-16 2016-03-16
PCT/US2017/022744 WO2017161137A1 (en) 2016-03-16 2017-03-16 Methods and compositions for treating a neurodegenerative disorder in a sphingotyped subject

Publications (2)

Publication Number Publication Date
EP3429590A1 EP3429590A1 (en) 2019-01-23
EP3429590A4 true EP3429590A4 (en) 2020-02-19

Family

ID=59851215

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17767536.0A Withdrawn EP3429590A4 (en) 2016-03-16 2017-03-16 Methods and compositions for treating a neurodegenerative disorder in a sphingotyped subject

Country Status (2)

Country Link
EP (1) EP3429590A4 (en)
WO (1) WO2017161137A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9802942B2 (en) * 2015-07-01 2017-10-31 Northwestern University Substituted 4-methyl-pyrrolo[1,2-A]pyrimidine-8-carboxamide compounds and uses thereof for modulating glucocerebrosidase activity

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016073891A1 (en) * 2014-11-06 2016-05-12 Lysosomal Therapeutics Inc. Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011338377B2 (en) * 2010-12-08 2016-08-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Substituted pyrazolopyrimidines as glucocerebrosidase activators
KR20170082577A (en) * 2014-11-06 2017-07-14 리소소말 테라퓨틱스 인크. Substituted pyrazolo(1,5-a)pyrimidines and their use in the treatment of medical disorders
WO2016164474A1 (en) * 2015-04-06 2016-10-13 The Trustees Of Columbia University In The City Of New York Predictive value of combined genetic enzymatic and lipidomic data in disease risk for lewy body disease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016073891A1 (en) * 2014-11-06 2016-05-12 Lysosomal Therapeutics Inc. Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MICHELLE M MIELKE ET AL: "Could plasma sphingolipids be diagnostic or prognostic biomarkers for Alzheimer's disease?", CLINICAL LIPIDOLOGY, vol. 7, no. 5, 1 October 2012 (2012-10-01), GB, pages 525 - 536, XP055392442, ISSN: 1758-4299, DOI: 10.2217/clp.12.59 *
See also references of WO2017161137A1 *

Also Published As

Publication number Publication date
EP3429590A1 (en) 2019-01-23
WO2017161137A1 (en) 2017-09-21

Similar Documents

Publication Publication Date Title
IL259795A (en) Methods and compositions for treating a serpinc1-associated disorder
EP3242262A4 (en) Payment authorization method and device
EP3302379A4 (en) Compositions and methods for treating pterygium
EP3099296A4 (en) Isoindoline compositions and methods for treating neurodegenerative disease
EP3426286A4 (en) Methods for treating hypophosphatasia in children
EP3277270A4 (en) Compositions and methods for treating anemia
HK1258529A1 (en) Methods and compositions for treating neurodegenerative and neuroinflammatory conditions
EP3307296A4 (en) Methods and compositions for treating aging-associated conditions
EP3200815A4 (en) Methods and compositions for treating cancer
EP3189074A4 (en) Compositions and methods for treating and preventing inflammation
IL264641A (en) Acetyl-leucine for use in treating neurodegenerative diseases
EP3458079A4 (en) Compositions and methods for treating acne
EP3405191A4 (en) Methods and compositions for treating hyperhidrosis
ZA201606673B (en) Compositions and methods for treating neurodegenerative diseases
EP3454885A4 (en) Peptides and methods for treating neurodegenerative disorders
HK1256298A1 (en) Compositions and methods for treating and preventing neurodegenerative disorders
EP3313387A4 (en) Methods and compositions for treating neurodegenerative disorders
EP3356598A4 (en) Compositions and methods for treating filler in papermaking
EP3262065A4 (en) Methods and compositions for treating dystroglycanopathy disorders
EP3445369A4 (en) Compositions and methods for treating dementia
EP3364965A4 (en) Methods and compositions for treating neurodegenerative diseases
EP3273970A4 (en) Methods and materials for treating cancer
EP3139744A4 (en) Methods and compositions for treating and preventing tinnitus
EP3429590A4 (en) Methods and compositions for treating a neurodegenerative disorder in a sphingotyped subject
EP3158084A4 (en) Compositions and methods for modulating neuronal degeneration

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20181015

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20200121

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 25/28 20060101ALI20200115BHEP

Ipc: A61K 31/519 20060101AFI20200115BHEP

Ipc: A61P 25/16 20060101ALI20200115BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20200818